Morning Briefing
Summaries of health policy coverage from major news organizations
Senate Panel Approves Azar Nomination Despite Democrats' Concerns Over His Ties To Pharma Industry
The Associated Press: Senate Panel Advances Trump Health Secretary Pick
A Senate committee has signed off on President Donald Trump's pick for health secretary, clearing the way for final confirmation of Alex Azar. The Finance Committee voted 15-12 on Wednesday to send Azar's nomination to the full Senate. Although the panel's vote was largely along party lines, Azar's confirmation hearings weren't nearly as contentious as the deliberations over his predecessor, Tom Price. (1/17)
The Washington Post: Senate Finance Committee Advances Alex Azar’s Nomination To Head HHS
If approved by the full Senate, Azar, a former executive for the Eli Lilly pharmaceutical company, would succeed President Trump’s first HHS secretary, Tom Price. The former congressman from Georgia resigned under pressure in September during an investigation of his use of private charter planes at taxpayer expense to attend official events. “Mr. Azar is well-credentialed to lead such a critical department at a time America’s health care system is facing difficult challenges,” Committee Chairman Orrin G. Hatch (R-Utah) said in a written statement. (Bernstein, 1/17)
The Hill: Senate Panel Advances Trump's Nominee For Health Secretary
Sen. Rand Paul (R-Ky.) is the lone Republican to have expressed concerns with Azar's nomination, stemming from the lack of an endorsement from Azar for allowing drugs to be imported from overseas. (Roubein, 1/17)
Los Angeles Times: Senate Panel Endorses Trump's Pick For Health Secretary
Azar — who as head of the mammoth agency will oversee the Medicare and Medicaid programs, the Food and Drug Administration, the National Institutes of Health and the Centers for Disease Control and Prevention — has pledged to prioritize key issues important to both Republicans and Democrats, including the opioid epidemic, the burden of healthcare costs on Americans and the rising price of pharmaceuticals. "Drug prices are too high," Azar told the Senate Committee on Health, Education, Labor and Pensions in November, pledging to look at ways to increase competition and stop drugmakers from gaming the system. But Azar's work at Lilly, which dramatically raised prices on its insulin product while he was at the company, has made many consumer advocates skeptical he will take on the powerful pharmaceutical industry. (Levey, 1/17)
